Four new multiple kinase inhibitors in the clinical trial stage for HER+

[heblaj01]

http://pubs.acs.org/cen/coverstory/84/8432cancer.html
August 7, 2006
Battling Breast Cancer
By targeting multiple HER-family receptors, small-molecule drugs could fill the therapeutic gaps left by Herceptin

In this informative article the expected mode of action of 4 new drugs in clinical trials is explained. They will hopefully be even more effective than Herceptin or Tykerb as they are supposed to inhibit two or more pathways & some growth factors & they could become follow up treatments to the 2 proven drugs when resistance sets in.

The current temporary name of these drugs is:

HKI-272.............Wyeth ...................(lung, breast cancers)
XL647.................Exelixis/genentech.. (breast)
ARRY-334543......Array Biopharma ......(lung,breast)
Pertuzumab........Genentech............. (breast)